Clover Health Investments, Corp. CLOV
4.29 USD -0.02 (-0.46%)
At closeNov 3, 2026, 6:36 PM EST
4.26 -0.03 -0.71%
After hours · Nov 3, 6:36 PM ET
4.19 Day range 4.37
1.58 52-week range 5.59
- YTD
- +82.55%
- 1 year
- +16.58%
Analyst view
Consensus: buy
Buy
Price target (mean) 5.50 +28.2% upside
Now 4.29
- Target (low)
- 5.00
- Target (mean)
- 5.50
- Target (high)
- 6.00
Ratings (0m) 5 3 buy · 2 hold · 0 sell
- Strong buy1
- Buy2
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 4
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.01 | 0.01 – 0.01 | 0.0033 | +203.0% | 738.42M | +48.7% | 1 |
| Next quarter | -0.02 | -0.02 – -0.02 | -0.0459 | +56.4% | 723.47M | +48.3% | 1 |
| Current year | 0.14 | 0.14 – 0.14 | 0.039 | +259.0% | 2.95B | +53.5% | 1 |
| Next year | 0.15 | 0.15 – 0.15 | 0.14 | +7.1% | 3.54B | +19.8% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Needham | Initiated | — | Buy |
| Aug 6, 2026 | UBS | Maintained | Neutral | Neutral |
| Jul 21, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 11, 2026 | UBS | Maintained | Neutral | Neutral |
| Jun 4, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 20, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 5, 2026 | Leerink Partners | Maintained | Market Perform | Market Perform |
| Jan 20, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 6, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 7, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 6, 2025 | UBS | Maintained | Neutral | Neutral |
| Mar 3, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Dec 17, 2024 | Craig-Hallum | Initiated | — | Buy |
| Oct 7, 2024 | UBS | Initiated | — | Neutral |
| Aug 11, 2023 | Citigroup | Maintained | Neutral | Neutral |
| Mar 6, 2023 | Canaccord Genuity | Maintained | — | Buy |
| Mar 6, 2023 | Credit Suisse | Maintained | — | Underperform |
| Nov 16, 2022 | Citigroup | Maintained | — | Neutral |
| Nov 8, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Aug 9, 2022 | Citigroup | Maintained | — | Neutral |
| Aug 9, 2022 | Credit Suisse | Maintained | — | Underperform |
| May 10, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Feb 25, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Feb 2, 2022 | Canaccord Genuity | Initiated | — | Buy |
| Feb 2, 2022 | Cowen & Co. | Upgrade | Underperform | Market Perform |
| Jan 19, 2022 | SVB Leerink | Initiated | — | Market Perform |
| Jan 7, 2022 | Credit Suisse | Downgrade | Neutral | Underperform |
| Nov 15, 2021 | Credit Suisse | Maintained | — | Neutral |
| Sep 10, 2021 | Cowen & Co. | Initiated | — | Underperform |
| Jul 12, 2021 | JP Morgan | Downgrade | Neutral | Underweight |